Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Nobili, Elena ^a,b   Salvado, M Dolores ^c   Folkersen, Lasse ^c   Castiglioni, Laura ^b   Kastrup, Jens ^d   Wetterholm, Anders ^c   Tremoli, Elena ^a,b   Hansson, Göran K ^c   Sironi, Luigi ^a,b   Haeggström, Jesper Z ^c   Gabrielsen, Anders ^c  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; INTERLEUKIN 6; LEUKOTRIENE C4 SYNTHASE; MONTELUKAST; PEPTIDOLEUKOTRIENE;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBROSIS; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; MOUSE; NONHUMAN; OXYGEN SUPPLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SLEEP APNEA SYNDROME;

AGED; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL HYPOXIA; CYSTEINE; DISEASE MODELS, ANIMAL; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKOTRIENES; MALE; MICE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RECEPTORS, LEUKOTRIENE; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; UP-REGULATION;

MUS;

EID: 84864363914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041786     Document Type: Article

References (28)

1. Goldman MD, Reeder MK, Muir AD, Loh L, Young JD, et al. (1993) Repetitive nocturnal arterial oxygen desaturation and silent myocardial ischemia in patients presenting for vascular surgery. J Am Geriatr Soc 41: 703-709.
2. Koehler U, Dubler H, Glaremin T, Junkermann H, Lubbers C, et al. (1991) Nocturnal myocardial ischemia and cardiac arrhythmia in patients with sleep apnea with and without coronary heart disease. Klin Wochenschr 69: 474-482.
3. Schafer H, Koehler U, Ploch T, Peter JH, (1997) Sleep-related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 111: 387-393.
4. Stanke-Labesque F, Back M, Lefebvre B, Tamisier R, Baguet JP, et al. (2009) Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 124: 364-370, 370 e361-362.
5. Li RC, Haribabu B, Mathis SP, Kim J, Gozal D, (2011) Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 184: 124-131.
6. Allen S, Dashwood M, Morrison K, Yacoub M, (1998) Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97: 2406-2413.
7. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, et al. (1992) Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 85: 230-236.
8. Haeggstrom JZ, Funk CD, (2011) Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 111: 5866-5898.
9. Wargovich T, Mehta J, Nichols WW, Pepine CJ, Conti CR, (1985) Reduction in blood flow in normal and narrowed coronary arteries of dogs by leukotriene C4. J Am Coll Cardiol 6: 1047-1051.
10. Jiang W, Hall SR, Moos MP, Cao RY, Ishii S, et al. (2008) Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 172: 592-602.
11. Becher UM, Ghanem A, Tiyerili V, Furst DO, Nickenig G, et al. (2011) Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury. J Mol Cell Cardiol 50: 570-577.
12. Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK, (1999) Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci U S A 96: 6920-6924.
13. Wang YX, (2005) Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. Neurobiol Aging 26: 309-316.
14. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, et al. (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New England Journal of Medicine 350: 29-37.
15. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36: 233-239.
16. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, et al. (2006) Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 103: 8161-8166.
17. Miller DT, Ridker PM, Libby P, Kwiatkowski DJ, (2007) Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 49: 1589-1599.
18. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, et al. (2006) A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38: 68-74.
19. Funk CD, (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4: 664-672.
20. Poeckel D, Funk CD, (2010) The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res 86: 243-253.
21. Ni NC, Yan D, Ballantyne LL, Barajas-Espinosa A, St Amand T, et al. (2011) A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J Pharmacol Exp Ther 339: 768-778.
22. Haeggstrom JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A, (2010) Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 396: 135-139.
23. Haeggstrom JZ, Wetterholm A, (2002) Enzymes and receptors in the leukotriene cascade. Cell Mol Life Sci 59: 742-753.
24. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y, (2009) GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A 106: 11685-11690.
25. Maekawa A, Kanaoka Y, Xing W, Austen KF, (2008) Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105: 16695-16700.
26. Cao RY, St Amand T, Grabner R, Habenicht AJ, Funk CD, (2009) Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 203: 395-400.
27. Ingelsson E, Yin L, Back M, (2012) Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 129: 702-707 e702.
28. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.